Flavonoids – the antioxidants that protect plants from viral infections – can now help to protect us from colds and ‘flu, too. These flavonoids are present in Cold & Flu Guard™ which, when sprayed into your mouth and nose, remains as a thin layer for up to three hours to trap unwanted viruses and bacteria. The patented natural active ingredient, known as Flavobac™, then envelops the trapped viruses and bacteria and inactivates them – just as they do to protect plants – so they can no longer reproduce or cause harm…
Durability of immune responses to the BNT162b2 mRNA vaccine
“Six months after receiving the second dose of the two-shot vaccine from Pfizer Inc and BioNTech SE, many recipients no longer have vaccine-induced antibodies that can immediately neutralize worrisome variants of the coronavirus, a new study suggests.”
This reinforces the need for protection beyond vaccination. Spray it with Cold & Flu Guard.
COLD & FLU GUARD™ could represent an important and novel complementary interventions in the fight against the Delta, Beta and Gamma Variants of Concern
BROSSARD, QC, Aug. 30, 2021 /CNW Telbec/ – New data released today shows that Cold & Flu Guard™ oral/nasal spray is more than 99% effective in-vitro against three of the four deadliest variants of the SARS-CoV-2 virus.
Flavobac™ Cold & Flu Guard™ (CNW Group/Oral Science International)
The results from the renowned Utah State University Institute of Antiviral Research in the US confirm that Cold & Flu Guard, is highly active against the Delta (India), Beta (South Africa) and Gamma (Japan/Brazil) variants of SARS-CoV-2..
COLD & FLU GUARD™ was developed for application in the nasal and oral cavity to help protect and reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe, Canada and USA, and available online in certain markets.
Global data indicates that vaccines against COVID-19 are highly effective in preventing hospitalisation and death, but that vaccinated individuals can still become infected and shed virus. Complementary interventions, like COLD & FLU GUARD™, could potentially be used to protect and reduce viral load at the primary site of initial infection.
“The findings indicate comparable potency for COLD & FLU GUARD against all three variants of concern compared with original strains of the virus. COLD & FLU GUARD™ can be used as supplementary preventative measures to reduce exposure to infectious droplets and potentially reducing the person-to-person transmission risk in close contact situations. Nasal and oral antisepsis have been recommended as part of a comprehensive plan to reduce the risk of virus transmission” said Dr Michael Glogauer, Chief Science Officer at OSI.
FLAVOBAC™ COLD & FLU GUARD™ is an oral and nasal spray product that forms a barrier to protect and prevent viral infections. It is based on a naturally occurring biochemical that help fight infections. It combats viruses by interfering with their ability to adhere to the oral and nasal mucosa. FLAVOBAC™ COLD & FLU GUARD™ has already been reported to kill “99.8% of the SARS-CoV-2 as well as many other respiratory viruses such as human Coronavirus, Influenza virus, Rhinovirus, and RSV. For more information consult www.coldandfluguard.com
“Many people with diabetes, heart disease, cancer, immunocompromised and those who can’t afford to be sick need more protection in addition to vaccine and other public health recommendations. COLD & FLU GUARD™ offers a new option to suppress viral spread by trapping and neutralizing the viral load that has entered the nose and mouth. This new data reinforces that COLD & FLU GUARD™ quickly kills SARS-CoV-2 variants of concern, making it an effective and convenient addition to protect against viruses that enter through the mouth and nose”, said Christian Sauvageau, President of OSI.
Oral Science International (OSI) is an innovation-driven company dedicated to developing and commercializing innovative bio-technologies, providing solutions to oral/nasal infections and inflammation. Oral Science International has a strong and passionate leadership team committed to innovative oral care and infection control technologies that enhance quality of life for people of all ages. We are committed to customer-centered design and science-driven innovation. We focus our efforts on providing safe, valuable and easy-to-use products for the world market. Our commitment to innovation, partnership and excellence is built upon the foundation of a culture that greatly values collaboration. We are guided by comprehensive research which we share through publications and presentations, and collaboration with all stakeholders. www.oralscience.com
Ref: UTAH State University Virucidal Assay against SARS-CoV-2, Institute for Antiviral Research, SARS2-578. August 17, 2021. (data on file)
SOURCE Oral Science International
COOPER PHARMA and OSI Sign Distribution Agreement to protect and prevent against respiratory viruses including the one that causes COVID-19
BROSSARD, QC and CASABLANCA, Morocco, Aug. 11, 2021 /CNW/ – Innovative natural broad spectrum organic barrier is needed to prevent viral respiratory infection. COOPER PHARMA and OSI signed a distribution agreement to market Flavobac™ Cold & Flu Guard™. Under the terms of this agreement, OSI grants COOPER PHARMA exclusive right to distribute Flavobac™ Cold & Flu Guard™ in Morocco and the United Arab Emirates (UAE). COOPER PHARMA and Affiliates will employ their sales, marketing and e-commerce expertise to distribute Flavobac™ Cold & Flu Guard™ once product registration is obtained from the Moroccan and UAE health authorities.
Flavobac™ Cold & Flu Guard™ will become an essential part of COOPER PHARMA’s medical solutions, to protect children, parents, health care professionals and society against respiratory viruses including SARS-CoV-2 which causes COVID-19. “COOPER PHARMA is committed to help reducing the impact of respiratory viral infection” said Ayman Cheikh-Lahlou, the CEO of COOPER PHARMA.
Christian Sauvageau, OSI’s President, said: “We are immensely proud of this opportunity to be working with such a forward thinking company as COOPER PHARMA. We have seen the complete determination of COOPER PHARMA to commercialise innovative solutions and are so pleased to be working with them. We are also thankful to The Harel Group for identifying COOPER PHARMA as a strategic partner and for facilitating the full transaction process from introduction to the execution of the final agreements with COOPER PHARMA.”
Flavobac™ Cold & Flu Guard™ is a formulation based on substance obtained from natural source. It combats viruses by interfering with their ability to adhere to the oral and nasal mucosa. Flavobac™ Cold & Flu Guard™ has been shown to kill “99.8% of the SARS-CoV-2 in 5 minutes as well as many other respiratory viruses such as human Coronavirus, Influenza virus, Rhinovirus, and RSV1. Flavobac™ Cold & Flu Guard™ is already registered in Europe, Canada and the USA. Efforts are underway to allow it to be used across the world. For more information consult www.coldandfluguard.com
“COOPER PHARMA is proud to receive distribution rights for Flavobac™ Cold & Flu Guard™ from our partner OSI so that we can help people and health care professionals to protect themselves against respiratory viral infection, while respecting of course and above all the health recommendations in terms of prevention and treatment against respiratory viruses and in particular SARS-CoV-2” said Ayman Cheikh-Lahlou, the CEO of COOPER PHARMA. “Innovative broad spectrum barrier to help reducing viral spread and viral loads is an important new option to protect against respiratory viruses. Flavobac™ Cold & Flu Guard™ can neutralize viruses that have entered the nose and mouth and act as “local sanitizers” to destroy viruses before they have the opportunity to cause an infection. As the leading pharmaceutical company in Morocco, COOPER PHARMA is glad to provide people with a new tool to safeguard themselves against respiratory viruses”, said Ayman Cheikh-Lahlou.
About COOPER PHARMA
Since 1933, Cooper Pharma, a Moroccan pharmaceutical company, has been supporting health professionals in the service of a mission: to increase everyone’s access to medicines. Cooper Pharma is today a leading laboratory in the national pharmaceutical industry, with its Cooper product line, covering over a hundred specialties and the major therapeutic areas. Alongside its own products, Cooper Pharma is the partner of about twenty multinationals for which it represents a hundred medicines, under license. Cooper Pharma is a producer, distributor and exporter of pharmaceutical specialties. Cooper Pharma is today a reference player in the Africa and Middle East region with commercial span in Europe. Cooper Pharma has nine pharmaceutical plants fully owned or in JV with local leaders over North Africa, West Africa, East Africa, Gulf Cooperation Council countries and Europe. For more information, please visit: http://cooperpharma.ma/en/
Oral Science International (OSI) is an innovation-driven company dedicated to developing and commercializing innovative bio-technologies, providing solutions to oral/nasal infections and inflammation. Oral Science International has a strong and passionate leadership team committed to innovative oral care and infection control technologies that enhance quality of life for people of all ages. We are committed to customer-centered design and science-driven innovation. We focus our efforts on providing safe, valuable and easy-to-use products for the world market. Our commitment to innovation, partnership and excellence is built upon the foundation of a culture that greatly values collaboration. We are guided bycomprehensive research which we share through publications and presentations, and collaboration with all stakeholders. www.oralscience.com
About The Harel Group
The Harel Group is a business development advisory firm with in-depth industry knowledge and wide network of contacts in the pharmaceutical, biotechnology, diagnostics and medical devices industries. The Harel Group supports clients that are looking to expand their global commercial footprint by identifying strategic partners and facilitating licensing and distribution arrangements.For more information, please visit: https://www.theharelgroup.com/
Bioflavonoid Spray Efficacy Against Respiratory Viruses, Z Sheikh, H Lerner, Oral Health, July 9, 2021
SOURCE Oral Science International
For further information: OSI Contact: Christian Sauvageau, President, Email: email@example.com; COOPER PHARMA Contact: Amine Hajoui, Head of OTC Business Development, Email: firstname.lastname@example.org